{
    "2020-12-08": [
        [
            {
                "time": "",
                "original_text": "“证券时报-润灵评级”医药行业上市公司ESG评估报告",
                "features": {
                    "keywords": [
                        "ESG",
                        "医药行业",
                        "上市公司",
                        "评估报告"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业2021年度投资策略：需求无止境 供给共繁荣",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资策略",
                        "需求",
                        "供给"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2020年12月投资月报：医药反弹持续性如何？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资月报",
                        "反弹",
                        "持续性"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国君医药 | 2021年度策略：需求无止境，供给共繁荣",
                "features": {
                    "keywords": [
                        "国君医药",
                        "年度策略",
                        "需求",
                        "供给"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}